{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:06:12Z","timestamp":1777392372655,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2020YFS0417"],"award-info":[{"award-number":["2020YFS0417"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFS0227"],"award-info":[{"award-number":["2021YFS0227"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Medicine Research Project","award":["S21030"],"award-info":[{"award-number":["S21030"]}]},{"name":"Sichuan Cancer Hospital Outstanding Youth Funding","award":["YB2021029"],"award-info":[{"award-number":["YB2021029"]}]},{"name":"The Education Program of Sichuan Province","award":["18ZB0241"],"award-info":[{"award-number":["18ZB0241"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aimed to determine the performance of <jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT used for preprocedural assessment of glioblastoma before radiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twelve glioblastoma patients having undergone incomplete surgical resection or biopsy were examined with <jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT and MRI scanning before radiotherapy. All patients had confirmed tumor residues according to findings of histopathological and\/or long-term clinical and radiological follow-ups. Lesion characterization data, including SUV<jats:sub>max<\/jats:sub> and tumor-to-background ratio (TBR) on PET\/CT were attained. PET\/CT and MRI findings were compared in terms of number of lesions. The correlation between immunohistochemistry, molecular expression, and PET\/CT parameters was also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT detected 16 FAPI-avid out of 23 lesions in 12 patients described on MRI. MRI was statistically different from <jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT for lesion detection according to the exact McNemar statistical test (<jats:italic>P<\/jats:italic>\u2009=\u20090.0156). The SUV<jats:sub>max<\/jats:sub> and TBR of the glioblastomas was 7.08\u2009\u00b1\u20093.55 and 19.95\u2009\u00b1\u200913.22, respectively. The sensitivity and positive predictive value (PPV) of <jats:sup>18<\/jats:sup>\u00a0F-FAPI PET were 69.6% and 100%, respectively. Neither the Ki-67 index nor the molecular expression was correlated with the FAPI-PET\/CT parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT detects glioblastomas at a lower rate than MRI. However, the 100% PPV of the examination may make it useful for differentiating controversial lesions detected on MRI. The <jats:sup>18<\/jats:sup>\u00a0F-FAPI-avid lesions are displayed more clearly probably due to a higher TBR. <jats:sup>18<\/jats:sup>\u00a0F-FAPI PET\/CT imaging might find application in glioblastoma biopsy and radiotherapy planning.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00952-w","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T06:02:38Z","timestamp":1671861758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Performance of 18\u00a0F-FAPI PET\/CT in assessing glioblastoma before radiotherapy: a pilot study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yutang","family":"Yao","sequence":"first","affiliation":[]},{"given":"Xiaofei","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Wenya","family":"Yin","sequence":"additional","affiliation":[]},{"given":"Ying","family":"Kou","sequence":"additional","affiliation":[]},{"given":"Xiaoxiong","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Xiao","family":"Jiang","sequence":"additional","affiliation":[]},{"given":"Shirong","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Yongli","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Jun","family":"Dang","sequence":"additional","affiliation":[]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[]},{"given":"Zhuzhong","family":"Cheng","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,12,24]]},"reference":[{"key":"952_CR1","doi-asserted-by":"publisher","first-page":"n1560","DOI":"10.1136\/bmj.n1560","volume":"374","author":"C McKinnon","year":"2021","unstructured":"McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021;374:n1560.","journal-title":"BMJ"},{"issue":"8","key":"952_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and european Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073\u2013113.","journal-title":"Neuro Oncol"},{"issue":"3","key":"952_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/neuonc\/noy133","volume":"21","author":"JY Kim","year":"2019","unstructured":"Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol. 2019;21(3):404\u201314.","journal-title":"Neuro Oncol"},{"issue":"2","key":"952_CR4","first-page":"477","volume":"290","author":"RL Wolf","year":"2019","unstructured":"Wolf RL. MRI of Recurrent Glioblastoma. Reliab Real Radiol. 2019;290(2):477\u20138.","journal-title":"Reliab Real Radiol"},{"issue":"6","key":"952_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.rcl.2019.07.003","volume":"57","author":"SB Strauss","year":"2019","unstructured":"Strauss SB, Meng A, Ebani EJ, Chiang GC. Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis. Radiol Clin North Am. 2019;57(6):1199\u2013216.","journal-title":"Radiol Clin North Am"},{"issue":"3","key":"952_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/jmri.27118","volume":"52","author":"R Bai","year":"2020","unstructured":"Bai R, Wang B, Jia Y, Wang Z, Springer CS Jr, Li Z, et al. Shutter-Speed DCE-MRI analyses of human Glioblastoma Multiforme (GBM) Data. J Magn Reson Imaging. 2020;52(3):850\u201363.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"952_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3174\/ajnr.A6983","volume":"42","author":"CJ Park","year":"2021","unstructured":"Park CJ, Han K, Kim H, Ahn SS, Choi D, Park YW, et al. MRI features may predict molecular features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas. AJNR Am J Neuroradiol. 2021;42(3):448\u201356.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"952_CR8","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3348\/kjr.2020.1433","volume":"22","author":"E Pak","year":"2021","unstructured":"Pak E, Choi KS, Choi SH, Park CK, Kim TM, Park SH, et al. Prediction of prognosis in Glioblastoma using Radiomics features of dynamic contrast-enhanced MRI. Korean J Radiol. 2021;22(9):1514\u201324.","journal-title":"Korean J Radiol"},{"issue":"2","key":"952_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/curroncol28020136","volume":"28","author":"J Kasper","year":"2021","unstructured":"Kasper J, Hilbert N, Wende T, Fehrenbach MK, Wilhelmy F, Jahne K, et al. On the prognosis of Multifocal Glioblastoma: an evaluation incorporating volumetric MRI. Curr Oncol. 2021;28(2):1437\u201346.","journal-title":"Curr Oncol"},{"key":"952_CR10","doi-asserted-by":"publisher","first-page":"105972","DOI":"10.1016\/j.clineuro.2020.105972","volume":"196","author":"A De Barros","year":"2020","unstructured":"De Barros A, Attal J, Roques M, Nicolau J, Sol JC, Charni S, et al. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: a retrospective observational study. Clin Neurol Neurosurg. 2020;196:105972.","journal-title":"Clin Neurol Neurosurg"},{"key":"952_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jocn.2019.01.022","volume":"63","author":"PYM Woo","year":"2019","unstructured":"Woo PYM, Ho JMK, Tse TPK, Lam SW, Mak CHK, Chan DTM, et al. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: a multicenter cohort study. J Clin Neurosci. 2019;63:134\u201341.","journal-title":"J Clin Neurosci"},{"key":"952_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.radonc.2021.01.040","volume":"158","author":"C Hassanzadeh","year":"2021","unstructured":"Hassanzadeh C, Rudra S, Ma S, Brenneman R, Huang Y, Henke L, et al. Evaluation of interim MRI changes during limited-field radiation therapy for glioblastoma and implications for treatment planning. Radiother Oncol. 2021;158:237\u201343.","journal-title":"Radiother Oncol"},{"issue":"4","key":"952_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/cco.2017.06.28","volume":"6","author":"G Shukla","year":"2017","unstructured":"Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6(4):40.","journal-title":"Chin Clin Oncol"},{"issue":"3","key":"952_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"952_CR15","doi-asserted-by":"publisher","first-page":"e0248193","DOI":"10.1371\/journal.pone.0248193","volume":"16","author":"J Bolcaen","year":"2021","unstructured":"Bolcaen J, Descamps B, Deblaere K, De Vos F, Boterberg T, Hallaert G, et al. Assessment of the effect of therapy in a rat model of glioblastoma using [18F]FDG and [18F]FCho PET compared to contrast-enhanced MRI. PLoS ONE. 2021;16(3):e0248193.","journal-title":"PLoS ONE"},{"issue":"5","key":"952_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1078-0432.CCR-20-1775","volume":"27","author":"A Seidlitz","year":"2021","unstructured":"Seidlitz A, Beuthien-Baumann B, Lock S, Jentsch C, Platzek I, Zophel K, et al. Final results of the prospective Biomarker Trial PETra: [(11)C]-MET-Accumulation in postoperative PET\/MRI predicts outcome after Radiochemotherapy in Glioblastoma. Clin Cancer Res. 2021;27(5):1351\u201360.","journal-title":"Clin Cancer Res"},{"key":"952_CR17","doi-asserted-by":"crossref","unstructured":"Ruiz-Lopez E, Calatayud-Perez J, Castells-Yus I, Gimeno-Peribanez MJ, Mendoza-Calvo N, Morcillo MA, et al. Diagnosis of glioblastoma by immuno-positron emission tomography. Cancers (Basel). 2021;14(1).","DOI":"10.3390\/cancers14010074"},{"issue":"4","key":"952_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/RLU.0000000000002460","volume":"44","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Soma T, Mukasa A, Tanaka S, Yanagisawa S, Momose T. Pattern of FDG and MET distribution in high- and Low-Grade Gliomas on PET images. Clin Nucl Med. 2019;44(4):265\u201371.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"952_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/RLU.0000000000000532","volume":"39","author":"MM D\u2019Souza","year":"2014","unstructured":"D\u2019Souza MM, Sharma R, Jaimini A, Panwar P, Saw S, Kaur P, et al. 11\u00a0C-MET PET\/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. Clin Nucl Med. 2014;39(9):791\u20138.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"952_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation Dosimetry and Biodistribution of (68)Ga-FAPI-46 PET imaging in Cancer Patients. J Nucl Med. 2020;61(8):1171\u20137.","journal-title":"J Nucl Med"},{"issue":"6","key":"952_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: Tracer Uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"issue":"8","key":"952_CR22","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"952_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","volume":"48","author":"H Chen","year":"2021","unstructured":"Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [(18)F]FDG PET\/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"952_CR24","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","volume":"61","author":"J Toms","year":"2020","unstructured":"Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting fibroblast activation protein: Radiosynthesis and preclinical evaluation of an (18)F-Labeled FAP inhibitor. J Nucl Med. 2020;61(12):1806\u201313.","journal-title":"J Nucl Med"},{"issue":"9","key":"952_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","volume":"61","author":"SA Koerber","year":"2020","unstructured":"Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The role of (68)Ga-FAPI PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience. J Nucl Med. 2020;61(9):1331\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"952_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET\/CT: Biodistribution and preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386\u201392.","journal-title":"J Nucl Med"},{"key":"952_CR27","doi-asserted-by":"crossref","unstructured":"Jin X, Wei M, Wang S, Wang G, Lai Y, Shi Y, et al. Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET\/CT. J Nucl Med. 2021.","DOI":"10.2967\/jnumed.121.262134"},{"issue":"12","key":"952_CR28","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00259-019-04444-y","volume":"46","author":"M Rohrich","year":"2019","unstructured":"Rohrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, et al. IDH-wildtype glioblastomas and grade III\/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET\/CT. Eur J Nucl Med Mol Imaging. 2019;46(12):2569\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2021.02.015","volume":"158","author":"L Zhao","year":"2021","unstructured":"Zhao L, Chen S, Chen S, Pang Y, Dai Y, Hu S, et al. (68)Ga-fibroblast activation protein inhibitor PET\/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55\u201361.","journal-title":"Radiother Oncol"},{"key":"952_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2020.06.040","volume":"150","author":"P Windisch","year":"2020","unstructured":"Windisch P, Rohrich M, Regnery S, Tonndorf-Martini E, Held T, Lang K, et al. Fibroblast activation protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol. 2020;150:159\u201363.","journal-title":"Radiother Oncol"},{"key":"952_CR31","doi-asserted-by":"publisher","first-page":"109021","DOI":"10.1016\/j.ejrad.2020.109021","volume":"127","author":"M Rohrich","year":"2020","unstructured":"Rohrich M, Floca R, Loi L, Adeberg S, Windisch P, Giesel FL, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. Eur J Radiol. 2020;127:109021.","journal-title":"Eur J Radiol"},{"key":"952_CR32","doi-asserted-by":"publisher","first-page":"649148","DOI":"10.3389\/fonc.2021.649148","volume":"11","author":"X Jiang","year":"2021","unstructured":"Jiang X, Wang X, Shen T, Yao Y, Chen M, Li Z, et al. FAPI-04 PET\/CT using [(18)F]AlF labeling strategy: automatic synthesis, Quality Control, and in vivo Assessment in Patient. Front Oncol. 2021;11:649148.","journal-title":"Front Oncol"},{"issue":"7","key":"952_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/MNM.0000000000001563","volume":"43","author":"Y Kou","year":"2022","unstructured":"Kou Y, Jiang X, Yao Y, Shen J, Jiang X, Chen S, et al. Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET\/CT imaging. Nucl Med Commun. 2022;43(7):847\u201354.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"952_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"952_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/path.4332","volume":"233","author":"A Clavreul","year":"2014","unstructured":"Clavreul A, Guette C, Faguer R, Tetaud C, Boissard A, Lemaire L, et al. Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. J Pathol. 2014;233(1):74\u201388.","journal-title":"J Pathol"},{"issue":"3","key":"952_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11060-011-0701-7","volume":"106","author":"A Clavreul","year":"2012","unstructured":"Clavreul A, Etcheverry A, Chassevent A, Quillien V, Avril T, Jourdan ML, et al. Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol. 2012;106(3):493\u2013504.","journal-title":"J Neurooncol"},{"issue":"10","key":"952_CR37","doi-asserted-by":"publisher","first-page":"13961","DOI":"10.1007\/s13277-016-5274-9","volume":"37","author":"P Busek","year":"2016","unstructured":"Busek P, Balaziova E, Matrasova I, Hilser M, Tomas R, Syrucek M, et al. Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma. Tumour Biol. 2016;37(10):13961\u201371.","journal-title":"Tumour Biol"},{"issue":"8","key":"952_CR38","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1007\/s13277-015-3259-8","volume":"36","author":"J Trylcova","year":"2015","unstructured":"Trylcova J, Busek P, Smetana K Jr, Balaziova E, Dvorankova B, Mifkova A, et al. Effect of cancer-associated fibroblasts on the migration of glioma cells in vitro. Tumour Biol. 2015;36(8):5873\u20139.","journal-title":"Tumour Biol"},{"key":"952_CR39","doi-asserted-by":"publisher","first-page":"778627","DOI":"10.3389\/fonc.2021.778627","volume":"11","author":"B Wang","year":"2021","unstructured":"Wang B, Zhang S, Wu X, Li Y, Yan Y, Liu L, et al. Multiple survival outcome prediction of Glioblastoma Patients based on multiparametric MRI. Front Oncol. 2021;11:778627.","journal-title":"Front Oncol"},{"issue":"1","key":"952_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijrobp.2004.01.026","volume":"59","author":"GP Mazzara","year":"2004","unstructured":"Mazzara GP, Velthuizen RP, Pearlman JL, Greenberg HM, Wagner H. Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation. Int J Radiat Oncol Biol Phys. 2004;59(1):300\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"952_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.radonc.2016.06.004","volume":"120","author":"M Harat","year":"2016","unstructured":"Harat M, Malkowski B, Makarewicz R. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: a prospective study. Radiother Oncol. 2016;120(2):241\u20137.","journal-title":"Radiother Oncol"},{"issue":"12","key":"952_CR42","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","volume":"47","author":"M Syed","year":"2020","unstructured":"Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020;47(12):2836\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"952_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ajco.12826","volume":"15","author":"E Wong","year":"2019","unstructured":"Wong E, Nahar N, Hau E, Varikatt W, Gebski V, Ng T, et al. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma. Asia Pac J Clin Oncol. 2019;15(1):5\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"952_CR44","doi-asserted-by":"crossref","unstructured":"Sledzinska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and predictive biomarkers in Gliomas. Int J Mol Sci. 2021;22(19).","DOI":"10.3390\/ijms221910373"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00952-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:05:15Z","timestamp":1672131915000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00952-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00952-w","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,24]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried\nout in accordance with the Declaration of Helsinki and approved by the Ethics\nCommittee of Sichuan cancer hospital (NO: SCCHEC-04-2020-001). The informed\nconsent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare\nthat the research was conducted in the absence of any commercial or financial\nrelationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}